Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

Completed · Phase 2

Conditions studied: Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome

In brief

The goal of this study is to determine whether post-transplant consolidation with azacitidine combined with donor lymphocyte infusion (DLI) is a safe and effective approach for the prevention of relapse in pediatric and young adult patients with hematologic malignancies who have undergone hematopoietic stem cell transplantation (HSCT).

Key facts

Study ID

NCT02458235

Run by

University of California, San Francisco

People needed

17

Starts

2015-06-02

Expected to finish

2019-03-15

Last updated by the study team

2020-10-12

Who can join

Age: any, up to 29. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients age 0 - 29.9 years undergoing allogeneic peripheral blood stem cell transplant
• Patients with acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL)
• Patients with juvenile myelomonocytic leukemia (JMML)
• Patients with myelodysplastic syndrome (MDS)

You may not qualify if…

• Patients who have had a prior transplant.
• Patients with Fanconi anemia or other cancer-predisposition syndromes
• Patients with expected survival <12 weeks
• Lansky score <60%

Where it is running

• University of California San Francisco — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.